The Wnt/β-catenin/T-cell factor 4 pathway up-regulates high-mobility group A1 expression in colon cancer

Cell Biochemistry and Function

Volumn 31, Issue 3, 2013, Pages 228-236

  Bush, Bethany M ^a,b   Brock, Ashton T ^a,c   Deng, Jiayue A ^a   Nelson, Ronald A ^a   Sumter, Takita Felder ^a  

^a WINTHROP UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Colon cancer; High mobility group A1 (HMGA1); Oncogene; TCF 4 target gene; Transcriptional activation; Wnt catenin TCF 4 pathway

Indexed keywords

BETA CATENIN; HIGH MOBILITY GROUP A PROTEIN; HIGH MOBILITY GROUP A1 PROTEIN; MESSENGER RNA; T CELL FACTOR PROTEIN; T CELL FACTOR PROTEIN 4; UNCLASSIFIED DRUG; WNT PROTEIN; ZINC;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL STRAIN HT29; COLON CANCER; COLON POLYPOSIS; CONTROLLED STUDY; DOWN REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE MUCOSA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE; WNT SIGNALING PATHWAY;

5' UNTRANSLATED REGIONS; ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; BETA CATENIN; COLONIC NEOPLASMS; DOWN-REGULATION; HCT116 CELLS; HMGA1A PROTEIN; HMGA1B PROTEIN; HT29 CELLS; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR 7-LIKE 2 PROTEIN; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; WNT PROTEINS; ZINC;

MUS;

EID: 84876093432     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.2876     Document Type: Article

References (77)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57-70.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646-674.
3. Fulda S. Tumor resistance to apoptosis. Int J Cancer 2009; 124(3): 511-515.
4. Blagosklonny MV. Molecular theory of cancer. Cancer Biol Ther 2005; 4(6): 621-627.
5. Finlay GJ. Genetics, molecular biology and colorectal cancer. Mutat Res 1993; 290(1): 3-12.
6. Rowan AJ, Lamlum H, Ilyas M, et al. APC mutations in sporadic colorectal tumors: A mutational "hotspot" and interdependence of the "two hits". Proc Natl Acad Sci USA 2000; 97(7): 3352-3357.
7. Lamlum H, Papadopoulou A, Ilyas M, et al. APC mutations are sufficient for the growth of early colorectal adenomas. Proc Natl Acad Sci USA 2000; 97(5): 2225-2228.
8. Lamlum H, Ilyas M, Rowan A, et al. The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis. Nat Med 1999; 5(9): 1071-1075.
9. Joslyn G, Carlson M, Thliveris A, et al. Identification of deletion mutations and three new genes at the familial polyposis locus. Cell 1991; 66(3): 601-613.
10. Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991; 66(3): 589-600.
11. Bodmer WF, Cottrell S, Frischauf AM, et al. Genetic analysis of colorectal cancer. Princess Takamatsu Symp 1989; 20: 49-59.
12. Schneikert J, Behrens J. The canonical Wnt signalling pathway and its APC partner in colon cancer development. Gut 2007; 56(3): 417-425.
13. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998; 58(6): 1130-1134.
14. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275(5307): 1787-1790.
15. Ilyas M, Tomlinson IP, Rowan A, Pignatelli M, Bodmer WF. Beta-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci USA 1997; 94(19): 10330-10334.
16. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997; 16(13): 3797-3804.
17. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 1996; 272(5264): 1023-1026.
18. Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA 1995; 92(7): 3046-3050.
19. Rubinfeld B, Souza B, Albert I, et al. Association of the APC gene product with beta-catenin. Science 1993; 262(5140): 1731-1734.
20. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997; 275(5307): 1784-1787.
21. Myant K, Sansom OJ. Wnt/Myc interactions in intestinal cancer: partners in crime. Exp Cell Res 2011; 317(19): 2725-2731.
22. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281(5382): 1509-1512.
23. Araki Y, Okamura S, Hussain SP, et al. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 2003; 63(3): 728-734.
24. Conacci-Sorrell ME, Ben-Yedidia T, Shtutman M, Feinstein E, Einat P, Ben-Ze'ev A. Nr-CAM is a target gene of the beta-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis. Genes Dev 2002; 16(16): 2058-2072.
25. Schwartz DR, Wu R, Kardia SL, et al. Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res 2003; 63(11): 2913-2922.
26. Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M, Pals ST. Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res 2008; 68(10): 3655-3661.
27. Li J, Li J, Chen B. Oct4 was a novel target of Wnt signaling pathway. Mol Cell Biochem 2012; 362(1-2): 233-240.
28. Valencia J, Hernandez-Lopez C, Martinez VG, et al. Transient beta-catenin stabilization modifies lineage output from human thymic CD34+CD1a- progenitors. J Leukoc Biol 2010; 87(3): 405-414.
29. Yan S, Zhou C, Zhang W, et al. beta-Catenin/TCF pathway upregulates STAT3 expression in human esophageal squamous cell carcinoma. Cancer Lett 2008; 271(1): 85-97.
30. Mann B, Gelos M, Siedow A, et al. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 1999; 96(4): 1603-1608.
31. Fedele M, Fusco A. HMGA and cancer. Biochim Biophys Acta 2010; 1799(1-2): 48-54.
32. Yie J, Liang S, Merika M, Thanos D. Intra- and intermolecular cooperative binding of high-mobility-group protein I(Y) to the beta-interferon promoter. Mol Cell Biol 1997; 17(7): 3649-3662.
33. Cleynen I, Van de Ven WJ. The HMGA proteins: A myriad of functions (Review). Int J Oncol 2008; 32(2): 289-305.
34. Reeves R, Beckerbauer L. HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim Biophys Acta 2001; 1519(1-2): 13-29.
35. Evans A, Lennard TW, Davies BR. High-mobility group protein 1(Y): metastasis-associated or metastasis-inducing? J Surg Oncol 2004; 88(2): 86-99.
36. Resar LM. The high mobility group A1 gene: transforming inflammatory signals into cancer? Cancer Res 2010; 70(2): 436-439.
37. Sumter TF. An emerging role for HMGA1a in human cancer & disease. Curr Mol Med 2012, in press.
38. Sarhadi VK, Wikman H, Salmenkivi K, et al. Increased expression of high mobility group A proteins in lung cancer. J Pathol 2006; 209(2): 206-212.
39. Wood LJ, Maher JF, Bunton TE, Resar LM. The oncogenic properties of the HMG-I gene family. Cancer Res 2000; 60(15): 4256-4261.
40. Wood LJ, Mukherjee M, Dolde CE, et al. HMG-I/Y, a new c-Myc target gene and potential oncogene. Mol Cell Biol 2000; 20(15): 5490-5502.
41. Reeves R, Edberg DD, Li Y. Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol Cell Biol 2001; 21(2): 575-594.
42. Xu Y, Sumter TF, Bhattacharya R, et al. The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res 2004; 64(10): 3371-3375.
43. Cleynen I, Huysmans C, Sasazuki T, Shirasawa S, Van de Ven W, Peeters K. Transcriptional control of the human high mobility group A1 gene: Basal and oncogenic ras-regulated expression. Cancer Res 2007; 67(10): 4620-4629.
44. Grade M, Hormann P, Becker S, et al. Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas. Cancer Res 2007; 67(1): 41-56.
45. Kim DH, Park YS, Park CJ, et al. Expression of the HMGI(Y) gene in human colorectal cancer. Int J Cancer 1999; 84(4): 376-380.
46. Fedele M, Bandiera A, Chiappetta G, et al. Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. Cancer Res 1996; 56(8): 1896-1901.
47. Grade M, Hummon AB, Camps J, et al. A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets. Int J Cancer 2010; 128(5): 1069-1079.
48. van der Zee JA, ten Hagen TL, Hop WC, et al. Differential expression and prognostic value of HMGA1 in pancreatic head and periampullary cancer. Eur J Cancer 2010; 46(18): 3393-3399.
49. Rahman MM, Qian ZR, Wang EL, et al. Frequent overexpression of HMGA1 and 2 in gastroenteropancreatic neuroendocrine tumours and its relationship to let-7 downregulation. Br J Cancer 2009; 100(3): 501-510.
50. Tesfaye A, Di Cello F, Hillion J, et al. The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. Cancer Res 2007; 67(9): 3998-4004.
51. Pierantoni GM, Agosti V, Fedele M, et al. High-mobility group A1 proteins are overexpressed in human leukaemias. Biochem J 2003; 372(Pt 1): 145-150.
52. Tallini G, Dal Cin P. HMGI(Y) and HMGI-C dysregulation: a common occurrence in human tumors. Adv Anat Pathol 1999; 6(5): 237-246.
53. Bandiera A, Bonifacio D, Manfioletti G, et al. Expression of HMGI(Y) proteins in squamous intraepithelial and invasive lesions of the uterine cervix. Cancer Res 1998; 58(3): 426-431.
54. Huang ML, Chen CC, Chang LC. Gene expressions of HMGI-C and HMGI(Y) are associated with stage and metastasis in colorectal cancer. Int J Colorectal Dis 2009; 24(11): 1281-1286.
55. Wang EL, Qian ZR, Rahman MM, et al. Increased expression of HMGA1 correlates with tumour invasiveness and proliferation in human pituitary adenomas. Histopathology 2010; 56(4): 501-509.
56. Flohr AM, Rogalla P, Bonk U, et al. High mobility group protein HMGA1 expression in breast cancer reveals a positive correlation with tumour grade. Histol Histopathol 2003; 18(4): 999-1004.
57. Belton A, Gabrovsky A, Bae YK, et al. HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. PLoS One 2012; 7(1): e30034.
58. Hommura F, Katabami M, Leaner VD, et al. HMG-I/Y is a c-Jun/activator protein-1 target gene and is necessary for c-Jun-induced anchorage-independent growth in Rat1a cells. Mol Cancer Res 2004; 2(5): 305-314.
59. Dhar A, Hu J, Reeves R, Resar LM, Colburn NH. Dominant-negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation. Oncogene 2004; 23(25): 4466-4476.
60. Nateri AS, Spencer-Dene B, Behrens A. Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development. Nature 2005; 437(7056): 281-285.
61. Hillion J, Dhara S, Sumter TF, et al. The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies? Cancer Res 2008; 68(24): 10121-10127.
62. Martinez Hoyos J, Fedele M, Battista S, et al. Identification of the genes up- and down-regulated by the high mobility group A1 (HMGA1) proteins: tissue specificity of the HMGA1-dependent gene regulation. Cancer Res 2004; 64(16): 5728-5735.
63. Foster LC, Wiesel P, Huggins GS, et al. Role of activating protein-1 and high mobility group-I(Y) protein in the induction of CD44 gene expression by interleukin-1beta in vascular smooth muscle cells. FASEB J 2000; 14(2): 368-378.
64. Morin PJ, Vogelstein B, Kinzler KW. Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci USA 1996; 93(15): 7950-7954.
65. Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992; 256(5057): 668-670.
66. Pedulla ML, Treff NR, Resar LM, Reeves R. Sequence and analysis of the murine Hmgiy (Hmga1) gene locus. Gene 2001; 271(1): 51-58.
67. Luongo C, Gould KA, Su LK, et al. Mapping of multiple intestinal neoplasia (Min) to proximal chromosome 18 of the mouse. Genomics 1993; 15(1): 3-8.
68. Behrens J, von Kries JP, Kuhl M, et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996; 382(6592): 638-642.
69. Wehkamp J, Wang G, Kubler I, et al. The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4. J Immunol 2007; 179(5): 3109-3118.
70. Sekine S, Shibata T, Sakamoto M, Hirohashi S. Target disruption of the mutant beta-catenin gene in colon cancer cell line HCT116: preservation of its malignant phenotype. Oncogene 2002; 21(38): 5906-5911.
71. Wu J, Richards MH, Huang J, et al. Human FasL gene is a target of beta-catenin/T-cell factor pathway and complex FasL haplotypes alter promoter functions. PLoS One 2011; 6(10): e26143.
72. Hristov AC, Cope L, Di Cello F, et al. HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Mod Pathol 2010; 23(1): 98-104.
73. Murphy JT, Tucker JM, Davis C, Berger FG. Raltitrexed increases tumorigenesis as a single agent yet exhibits anti-tumor synergy with 5-fluorouracil in ApcMin/+ mice. Cancer Biol Ther 2004; 3(11): 1169-1176.
74. Dolde CE, Mukherjee M, Cho C, Resar LM. HMG-I/Y in human breast cancer cell lines. Breast Cancer Res Treat 2002; 71(3): 181-191.
75. Berlingieri MT, Pierantoni GM, Giancotti V, Santoro M, Fusco A. Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene 2002; 21(19): 2971-2980.
76. Scala S, Portella G, Fedele M, Chiappetta G, Fusco A. Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc Natl Acad Sci USA 2000; 97(8): 4256-4261.
77. Akaboshi S, Watanabe S, Hino Y, et al. HMGA1 is induced by Wnt/beta-catenin pathway and maintains cell proliferation in gastric cancer. Am J Pathol 2009; 175(4): 1675-1685.